

*Appendix to Synergistic effects of blood
pressure-lowering drugs and statins:
Systematic review and meta-analysis*

Johan Sundström, MD PhD; Gullik Gulliksson, MD; Marcus Wirén, MD

Department of Medical Sciences, Uppsala University, and Uppsala Clinical Research center (UCR). Uppsala, Sweden

Appendix Table 1. Baseline characteristics of included trials

Trial	HOPE-3 ¹	SCAT ²	BCAPS ³	PREVEND-IT ⁴	ENCORE ⁵	Respond ⁶	ASCOT ⁷
Statin factor	Rosuvastatin vs. placebo	Simvastatin vs. placebo	Fluvastatin vs. placebo	Pravastatin vs. placebo	Fluvastatin vs. placebo	Atorvastatin vs. placebo	Atorvastatin vs. placebo
BPRx factor	Candesartan & HCTZ vs. placebo	Enalapril vs. placebo	Metoprolol vs. placebo	Fosinopril vs. placebo	Nifedipine vs. placebo	Atenolol in two different doses vs. placebo	More (amlodipine & perindopril) vs. less (atenolol & BFTZ)
Mean follow-up, w	291	208	157	200	26	8	172
Patients, n	12,705	460	793	864	343	1,660	10,305
Mean age, y	65.7	61	61.8	51	56-59	58.3	63
Men %	53.8	89	45.5	65	41-55	53.3	81
Smoking, %	27.7	15	30.8	31-34	NA	NA	32-33
Previous CVD, %	0	70	4.3	3.4	100	28.3	13-14
Type-2 diabetes, %	5.8	11	3.2	2.3-2.8	NA	14.7	24.3-24.8
Hypertension, %	37.9	36	12.2	0	41	100	100

Appendix to *Synergistic effects of blood pressure-lowering drugs and statins: Systematic review and meta-analysis*

Mean SBP, mmHg	138.1	130	138.9	130	130.9	148.4	164
Mean DBP, mmHg	81.9	78	84.7	76	76.3	91.8	95
Mean total cholesterol, mM	5.2	5.2	6.12	5.8	5.28	NA	5.48
Mean LDL-cholesterol, mM	3.3	3.3-3.4	4.1-4.2	4.0-4.1	3.44	NA	3.4-3.5

CVD, cardiovascular disease; SBP, systolic blood pressure; DBP, diastolic blood pressure, LDL, low-density lipoprotein; HCTZ, hydrochlorothiazide; BFTZ, bendroflumethiazide; NA, not applicable.

Appendix Table 2. Outcome variables and treatment effects on risk factors

Trial	HOPE-3 ¹	SCAT ²	BCAPS ³	PREVEND-IT ⁴	ENCORE ⁵	Respond ⁶	ASCOT ⁷
MACE	CV death, MI, stroke	Death, MI,	Death, stroke	NA	CV death	NA	Fatal CHD, MI
MACE-plus	CV death, MI, stroke, resuscitated cardiac arrest, heart failure, revascularization	NA	NA	CV death, MI, coronary ischemia, PAD, stroke, heart failure	NA	NA	Total cardiovascular events and procedures
SBP change	-4 vs. -10 placebo/less vs. active/more (mmHg)	-1.3 vs. -5.2	NA	Approx. +1 vs. 0	0 vs. 0	NA	-25.7 vs. -27.5
DBP change	-2.7 vs. -5.7 placebo/less vs.	-0.35 vs. -3.3	NA	Approx. +2 vs. 0	0 vs. 0	NA	-15.6 vs. -17.7

Appendix to *Synergistic effects of blood pressure-lowering drugs and statins: Systematic review and meta-analysis*

active/more

(mmHg)

Total cholesterol NA +0.15 vs. -1.09 NA Approx. -0.2 vs. -1.0 NA NA -0.27 vs. -1.27

change placebo vs.

active (mM)

LDL-cholesterol Approx. -0.10 vs. -1.16 +0.08 vs. -1.06 NA Approx. -0.1 vs. -1.0 NA NA -0.17 vs. -1.12


change placebo vs.

active (mM)

MACE, major adverse cardiovascular events; SBP, systolic blood pressure; DBP, diastolic blood pressure, LDL, low-density lipoprotein; CV, cardiovascular; MI, myocardial infarction; PAD, peripheral arterial disease; CHD, coronary heart disease; NA, not applicable; Approx., approximate numbers extracted from published figures.

Appendix to *Synergistic effects of blood pressure-lowering drugs and statins: Systematic review and meta-analysis*

Appendix Figure 1. Risk of publication bias



MACE, major adverse cardiovascular events; SE, standard error; RR, risk ratio.


Appendix to *Synergistic effects of blood pressure-lowering drugs and statins: Systematic review and meta-analysis*

Appendix Figure 2. Risk of bias per trial

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
ASCOT LLA	+	+	?	+	+	+	+
BCAPS	?	?	?	+	?	+	+
ENCORE I	?	?	?	+	?	+	+
HOPE-3	+	+	+	+	+	+	+
PREVEND IT	+	+	+	+	+	+	+
Respond	+	+	+	+	?	?	?
SCAT	+	+	+	?	+	+	+


Appendix to *Synergistic effects of blood pressure-lowering drugs and statins: Systematic review and meta-analysis*

Appendix Figure 3. Risk of bias overall



Appendix to Synergistic effects of blood pressure-lowering drugs and statins: Systematic review and meta-analysis

Appendix Figure 4. Forest plots of individual trials



References

1. Yusuf S, Lonn E, Pais P, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. *N Engl J Med* 2016.
2. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). *Circulation* 2000;102:1748-54.
3. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). *Circulation* 2001;103:1721-6.
4. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. *Circulation* 2004;110:2809-16.
5. Investigators E. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). *Circulation* 2003;107:422-8.
6. Preston RA, Harvey P, Herfert O, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. *Journal of clinical pharmacology* 2007;47:1555-69.

Appendix to *Synergistic effects of blood pressure-lowering drugs and statins: Systematic review and meta-analysis*

7. Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006;27:2982-8.